Rituximab is a monoclonal antibody currently being investigated as a potential therapy for multiple sclerosis.

Rituximab is an approved treatment for various types of blood cancer, and is marketed under the name Rituxan (in the U.S.) and MabThera (in Europe).

How rituximab works

Rituximab is a monoclonal antibody (a protein designed to target and attach to a specific protein) that interferes with the growth and spread of leukemia and lymphoma cancer cells. It works by targeting thee CD20 antigen, a substance found on the surface of certain immune cells called B-cells. Rituximab binds to the antigen on the cell surface which activates B-cell death. Because B-cells contribute to myelin damage in multiple sclerosis, rituximab may be helpful for treating the disease.

Studies involving rituximab for RRMS

Early studies of rituximab in people with neuromyelitis optica (NCT00501748) tested the drug’s safety. Although preliminary results from a group of eight people with neuromyelitis optica showed that B-cell depletion may enhance neurological recovery from attacks, there is still no published data from this study.

Rituximab has undergone other clinical studies in patients with different types of MS.

A Phase 2 study (NCT00097188) evaluated the safety and effectiveness of rituximab in adults with remitting-relapsing multiple sclerosis  (RRMS). Participants showed reduced numbers of new brain lesions and a 50% reduction in relapses.

A Phase 2/3 study (NCT00087529) evaluated the safety and effectiveness of rituximab in adults with primary progressive multiple sclerosis (PPMS). This trial compared rituximab to a placebo. Though rituximab did not prove effective, it was safe for people with PPMS.

A study (NCT01212094) involving people with secondary progressive multiple sclerosis (SPMS) was terminated because cerebrospinal fluid biomarkers failed to reach the criteria for continuation. This trial included 27 people with SPMS who received rituximab injections intrathecally (into the spine).

There are no Phase 3 trials currently planned for rituximab in MS, though the drug is licensed for other diseases and is currently used off-label for MS. Off-label use of rituximab for MS has received positive response — the observed annualized relapse rate and MRI disease activity were low during rituximab treatment, providing evidence that it is a safe and effective treatment for MS for up to 2 years. The compiled data for the outcome of off-label rituximab use in MS patients has been analysed and published in the scientific journal, Neurology.

Note: Multiple Sclerosis News Today is strictly a news and information website about the disease. It does not provide medical advice, diagnosis, or treatment. This content is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition. Never disregard professional medical advice or delay in seeking it because of something you have read on this website.

 

MS News that Caught My Eye Last Week: MS Misdiagnoses, Mineral Intake Risk Study, Hormonal Changes, Rituximab and Vitamin D

MS Misdiagnosis Too Common, Puts Patients in Unnecessary Peril from Therapies, Study Reveals Many people who have multiple sclerosis (MS) report that it’s taken doctors years to come up with their diagnoses. So, it’s interesting to read a story about the opposite: those whose MS diagnoses were incorrect. This supports my belief that too many […]

Higher Vitamin D Levels in Rituximab-treated MS Patients Linked to Lower Inflammatory Activity, Study Suggests

Rituximab-treated multiple sclerosis (MS) patients who take vitamin D supplements have less inflammatory activity, a study reports. Increased levels of vitamin D were associated with beneficial treatment outcomes, such as better self-perceived health and reduced levels of the inflammation marker C-reactive protein (CRP). The study, “Inflammatory activity and vitamin D levels in an MS population treated […]

MS News that Caught My Eye Last Week: New DMT, Stem Cell Trial, Pediatric MS Treatment Study

FDA Will Review New Drug Application of Diroximel Fumarate for Relapsing Forms of MS The good news: Another disease-modifying therapy (DMT) has taken a step toward approval in the U.S. The discouraging news: It’s another DMT designed to treat relapsing forms of multiple sclerosis. More than a dozen of those treatments are currently available. When […]

#ACTRIMS2019 – No Evidence of Disease Activity Seen in POMS Adolescents Taking Rituximab, Small Study Shows

Data supporting the off-label use of rituximab in adolescents with pediatric-onset multiple sclerosis (POMS) was presented at the Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS) Forum 2019. The session, titled “No Evidence of Disease Activity in the Majority of Pediatric-Onset Multiple Sclerosis Patients Receiving Rituximab,” was presented by Nikita Shukla, MD, from the Texas Children’s Hospital/Baylor […]

Need to Know: The Link Between the Epstein-Barr Virus and MS

Editor’s note: “Need to Know” is a series inspired by common forum questions and comments from readers. Have a comment or question about multiple sclerosis? Visit our forum. This week’s question is inspired by the forum topic “Can there be a connection between Epstein-Barr virus and MS?“, from April 26, 2018. What we know about MS […]

Top 10 Multiple Sclerosis Stories of 2018

Multiple Sclerosis News Today brought you daily coverage of key findings, treatment developments, and clinical trials related to multiple sclerosis (MS) throughout 2018. We look forward to reporting more news to patients, family members, and caregivers dealing with MS during 2019. Here are the top 10 most-read articles of 2018, with a brief description of what […]

#ECTRIMS2018 – Rituximab for MS Does Not Increase Cancer Risk Compared to Gilenya and Tysabri, Swedish Study Finds

Treatment of multiple sclerosis (MS) patients with rituximab does not increase breast cancer risk in women, and is not associated with a higher risk for malignant cancer of any type in men or women, when compared to Gilenya (fingolimod) or Tysabri (natalizumab), according to a nationwide study in Sweden. The study, “Cancer risk among Swedish multiple […]

#ECTRIMS2018 – Lower Mortality Rate in US, Sweden for MS Patients Treated With Rituximab, Study Reports

Treatment of multiple sclerosis (MS) patients with rituximab leads to lower-than-reported mortality rates, according to a large real-world study in the U.S. and Sweden. The findings also revealed no deaths due to infusion reactions or to systemic inflammation. The study, “Mortality rates in large US and Swedish rituximab-treated multiple sclerosis cohorts,” was presented at the 34th […]

How B-cells Work to Promote T-cell Attacks on Myelin That Lead to MS Detailed in Study

B-cells in the immune system play an important role in the unfolding of inflammation and brain lesions in multiple sclerosis (MS), largely by how they influence the actions of another immune system cell, called T-cells, a new study reports. Its findings help explain why therapies like Ocrevus and off-label use of rituximab, both of which […]